companydata.dkResistance Oncology ApS: Financial statements 2018
CVR: 36945125
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -14,500 and a net result of DKK -12,643 compared with DKK 1,147,497 the year before. Equity amounted to DKK -24,797.
- Gross Profit
- -14,500 kr.
- Profit/Loss
- -12,643 kr.
- Equity
- -24,797 kr.
- Total Assets
- 43,403 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -15 t. | -13 t. | -25 t. | - |
| 2017 | - | 51 t. | 1.1 mio. | -12 t. | 0 |
Keep an eye on Resistance Oncology ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2018
Resistance Oncology ApS has published its annual report for 2017. Gross profit came to DKK 51,356, and the net result was DKK 1,147,497.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Nils Aage Brünner and Kasper Pasternak Jørgensen. The company is owned by TIMPCO NB ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees. In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity amounted to DKK 325,631.